Literature DB >> 14997762

[A case of synchronous esophageal and gastric cancer successfully treated by combination TS-1/CDDP therapy with irradiation].

Masashi Takemura1, Harushi Osugi, Shigeru Lee, Shinichi Taguchi, Masahiro Kaneko, Yoshinori Tanaka, Kenichirou Fukuhara, Yuushi Fujiwara, Satoshi Nishizawa, Hiroaki Kinoshita, Shigeru Harada.   

Abstract

We report a case of synchronous esophageal and gastric cancer in a patient with severe liver dysfunction who was treated successfully using TS-1/CDDP therapy combined with irradiation therapy. A 56-year-old man with a chief complaint of dysphagia was diagnosed with thoracic esophageal cancer by endoscopy, and was referred to our hospital. Synchronous esophageal and gastric cancer were diagnosed by endoscopy and barium swallow. The preoperative diagnosis was T3N0M0, Stage II esophageal cancer and T1N0M0, Stage I A gastric cancer, both of which were diagnosed to be resectable. However, surgery was contraindicated because of severe liver dysfunction, due to an ICG15 of 35%. TS-1 (80 mg/day) and CDDP (3 mg/day) therapy was combined with irradiation, 60 Gy given in a T-pattern to the mediastinum. The patient did not suffer any side-effects, and endoscopy performed 44 days after the start of treatment showed that the esophageal lesion was now only a scar. Only a slight elevation of the esophagus was seen by endoscopy 219 days after the start of the therapy. The patient is currently undergoing only TS-1 treatment as an outpatient and is under observation. No metastasis to the liver or any other organ has been detected. TS-1 and CDDP therapy combined with radiotherapy appears to be effective in treating thoracic esophageal cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14997762

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  1 in total

1.  Esophageal papillomatosis complicated by squamous cell carcinoma.

Authors:  T Attila; A Fu; N Gopinath; C J Streutker; N E Marcon
Journal:  Can J Gastroenterol       Date:  2009-06       Impact factor: 3.522

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.